Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEO-201 bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Precision Biologics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NEO-201 bispecific antibody is an engineered therapeutic candidate developed by Precision Biologics. It is derived from the NEO-201 monoclonal antibody, which specifically targets truncated O-glycans (such as Core 1 and Core 2 O-glycans) that are expressed on various solid and hematological tumors but absent in healthy tissues. As a bispecific antibody, it is designed to simultaneously bind to these tumor-associated glycans and a second target, typically an immune effector cell, to facilitate targeted tumor cell killing. It is currently in preclinical development for the treatment of various tumor types.
- Other names
- NEO-201 Engineered (Bispecific)
02
Targets
Carcinoembryonic antigen-related cell adhesion molecule 5/6 tumor-associated O-glycan variantssTn (Sialyl-Tn antigen)
Beyond the preview
Go deeper on NEO-201 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEO-201 bispecific antibody.